Ipsen and Day One in ex-US tovorafenib deal for most common childhood brain tumor

Mid-size French drugmaker Ipsen (Euronext: IPN) and California’s Day One Biopharmaceuticals (Nasdaq: DAWN) have announced a global partnership, outside the USA, for tovorafenib.

Ipsen has secured rights in these countries for the oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.

Tovorafenib was granted Orphan Drug Designation and received US Food and Drug Administration (FDA) approval in April 2024 as a monotherapy treatment for patients six months and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. It is marketed as Ojemda in the USA.